Taha Qazi, MD: Finding Upadacitinib's Role in Crohn's Disease
Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.
Linda Stein Gold, MD: Phase 4 Data on Risankizumab for Moderate Plaque Psoriasis
In this interview with Dr. Gold, she describes her team’s recent findings from a phase 4 head-to-head study on risankizumab for psoriasis patients.
Nathan Steinle, MD: Long-Term Efficacy of Pegcetacoplan in GALE Extension Study
Presented at ASRS 2023, pegcetacoplan injection showed increasing treatment effects over 30 months for patients with geographic atrophy, with a consistent safety profile to previous phase 3 data.
Kevin J. Blinder, MD: Feasibility of Home Optical Coherence Tomography for nAMD
Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.
Sophie J. Bakri, MD: The Substantial Burden of Geographic Atrophy
At ASRS 2023, results from the MOSAIC study indicate the substantial burden of geographic atrophy on patients and their caregivers across the United States and Canada.
Julia Moore Vogel, PhD, MBA: How Do We Define Long Covid Patients?
Vogel reviews the struggles behind adequately diagnosing long Covid and quantifying its impact of disease at this time of clinical research.
Julia Moore Vogel, PhD, MBA: Long Covid Care Lacks Urgency
Lungcast's July episode guest discusses how long Covid therapy development is still about 5 years away from the market.
Crisis Point: Disparities in Cardiovascular Health
Crisis Point returns with an episode on cardiometabolic health disparities, as 3 experts unravel the scope of the crisis, from its historical basis to ongoing social determinants of health in the modern age.
The Prospect of Once-Weekly Basal Insulin, with Juan Frias, MD
Juan Frias, MD, discusses the potential impact of an FDA approval for once-weekly insulin icodec based on data observed within the ONWARDS program.
Viral Shah, MD: Time in Range Associated with Diabetic Retinopathy in T1D
A 7-year longitudinal analysis presented at ADA 2023 suggests time in range was associated with an increased risk of diabetic retinopathy in people with type 1 diabetes.
Breaking Down Tirzepatide and SURMOUNT-2 Data, with W. Timothy Garvey, MD
At ADA 2023, we sat down with W. Timothy Garvey, MD, to learn more about the safety and efficacy of tirzepatide in the SURMOUNT-2 trial and how the results complement SURMOUNT-1.
Ward Fickweiler, MD, PhD: Diabetic Retinopathy Inversely Associated with AMD
An analysis at ADA 2023 presents novel findings on the inverse association between clinical and biochemical factors in diabetic retinopathy and age-related macular degeneration.
Dawn Eichenfield, MD: Identifying Allergies in Pediatric Dermatology
While contact dermatitis is difficult to distinguish in children, there has become a greater collaboration between allergic and dermatologic specialists in managing conditions like atopic dermatitis.
Hilary Baldwin, MD: IDP-126 May Change Acne Management
The first triple-combination topical drug for acne may be available by the end of this year. One expert has high hopes for it.
Matthew Zirwas, MD: Ruxolitinib Cream and the Eczema JAK Inhibitor Era
Zirwas touts topical ruxolitinib's rapid, effective treatment of atopic dermatitis, and reviews the safety outcomes associated with JAK inhibitors.
Amit Pandya, MD: The Discovery of Oral Tranexamic Acid for Melasma
Pigmentary disorders including melasma are difficult to treat and complex. The leading agent for one expert was uncovered by unique circumstances.
Dawn Eichenfield, MD: Tips for Managing Severe Acne
From addressing the rare acne fulminans to utilizing narrow-spectrum antibiotics, the modern field of acne treatment is more complicated than it seems.
Hilary Baldwin, MD: The Surge of Rosacea Treatment Options
In the span of a decade, agents like topical ivermectin, minocycline and benzoyl peroxide has provided more opportunities to achieve clear skin for rosacea patients.
Amit Pandya, MD: Ruxolitinib Cream in Real-World Vitiligo Patients of Color
The trial investigator reviews disparities in patient needs and treatment outcomes based on their skin complexion, 1 year after ruxolitinib's FDA approval.
Melodie Young, MSN, ANP-c: Managing Comorbid Psoriatic Disease
Often lost in the fray of new drug development is the need to reinforce improved behavioral health, explains a longtime dermatology nurse practitioner.
Matthew Zirwas, MD: How Tapinarof Could Address Adult-Onset Atopic Dermatitis
On the basis of discovery into what drives adult-onset eczema, the novel drug may provide a unique benefit for impacted patients.
Nemolizumab Rapidly Improves EASI, SCORAD Scores for Atopic Dermatitis
A post hoc analysis shows the investigative drug significantly improved atopic dermatitis symptoms versus placebo as soon as the first week into a phase 2 trial.
Melodie Young, MSN, ANP-c: Keeping up with Dermatology's Advances
It's been a whirlwind few years for dermatology. The nurse practitioner discusses modern care teams, comorbid psoriatic disease, and expanding patient inclusion in clinical trials.
Albert Yan, MD: Navigating Advances to Acne Therapies, Monitoring
Yan discusses how acne care strategies have been bolstered—and complicated—by pharmacotherapy and telemedicine developments.
Matthew Zirwas, MD: How Do Emerging HS Treatments Line Up?
With multiple drug classes working toward FDA indication, a dermatologists explains his strategy for managing hidradenitis suppurativa.
Albert Yan, MD: Detecting Pediatric Skin Disease with the Microbiome, Technology
The CHOP pediatric dermatology director reviews recent breakthroughs in understanding complex pathophysiology of skin diseases.
Matthew Zirwas, MD: Roflumilast Foam for Seborrheic Dermatitis
The investigator explains why he believes the PDE4 inhibitor is "as close to a perfect drug as you can hope for in seborrheic dermatitis."
Addressing Disparities in Cardiometabolic Health with Joshua J. Joseph, MD, MPH
At the 7th Annual Heart in Diabetes meeting, Joseph discussed the need to advance equity in diabetes management, from clinical practice to community-based interventions.
Michael C. Cameron, MD: Reflecting on Real-World Abrocitinib
An investigator argues for greater prescriber understanding and communication of real-world efficacy and safety outcomes for the latest oral JAK inhibitor approved for atopic dermatitis.
Jennifer Hsiao, MD: JAK Inhibitors for Hidradenitis Suppurativa
Oral JAK-1 inhibitors upadacitinib and povorcitinib are showing significant benefit for patients with HS, and may soon be up for FDA decision.